Friday, 29 January 2016

Freelancing in Bioinformatics? It's happening here...uBiome FASTQ

http://www.guru.com/jobs/ubiome-raw-data-fastq-files-analysis/1210516#proposalModal

Any takers to help walk this guy through analysing ubiome raw fastq files?

p.s. I wasn't aware that ubiome gives out fastq files?


Sunday, 13 December 2015

Kaggle Genentech Cervical Cancer Screening Competition

Genentech Cervical Cancer Screening
$100,000
Cervical cancer is the third most common cancer in women worldwide. In this competition, Genentech is asking you to join their mission to help prevent cervical cancer. Given a dataset of de-identified health records, your challenge is to predict which women will not be screened for cervical cancer on the recommended schedule. Identifying at-risk populations will make education and intervention more effective, ideally ultimately reducing the number of women who die from this disease. This competition is only open to Kaggle Masters.

For more details
Visit 
https://www.kaggle.com/c/cervical-cancer-screening

Wednesday, 9 December 2015

JDs: Google Life Sciences (Verily) is looking for a Genomics Scientist


https://www.google.com/about/careers/search?src=Online/Google+Website/Life+Sciences#!t=jo&jid=147445001&

Preferred qualifications
  • 2 years of post-graduate experience.
  • Extensive lentiviral gene delivery and cell culture experience.
  • Demonstrated expertise in both experimental and computational analysis.
  • Fluency in standard bioinformatics tools, Python, Perl, and R.
  • Excellent creativity, decision making, and troubleshooting skills.
  • Strong analytical and organizational skills along with strong written and oral communication skills, as demonstrated through publications and presentations.



Author comments: Gosh ... expertise in BOTH experimental and computational analysis ... 

Verily, I swear ... Google Life Sciences has a new name

V is no longer for Vendetta, under Alphabet, the new Google holding company, V is for Verily. Google Life Sciences division is now known as Verily
The front page is a splash of pulsating magenta and purple with the words 
"How can we use technology to create a true picture of human health?"
Reportedly in Stat News, CEO Andy Conrad said:"Only through the truth are we going to defeat Mother Nature"
Hmmm lofty aims indeed, not sure why you can't work WITH Mother Nature because I am pretty sure she wins all the time. 

Abandoned Shopping Mall Taken Over By Fish In Bangkok Image credits: Jesse Rockwell

Thursday, 19 November 2015

AIA-Konica Minolta Digital Health Hackathon




- AIA Group Limited and Konica Minolta, Inc. today jointly launched the 'AIA - Konica Minolta Digital Health Accelerator' in Singapore. The 12 week programme supports entrepreneurs and businesses to deliver innovative solutions through integrating data to healthcare delivery.
The Singaporean Government's spend on Healthcare in Singapore is expected to double to SG$8 billion by the end of 2015, from SG$4 billion in 2011. 'Digital Health' solutions present one of the most promising growth segments in the healthcare sector, as innovative solutions empower people to better manage and improve their health and provide better diagnostics and treatment options using sensors, data and imaging that are now within the consumer ecosystem.

 To learn about the accelerator program see here 

Monday, 9 November 2015

JDs : what's Product Content Projects and Illumina Concierge Service projects?

Looking at job descriptions again ... the question that is circling in my head is ....

what's Product Content Projects and Illumina Concierge Service projects?
Sounds POSH ....


https://www.linkedin.com/jobs2/view/83031616?trk=job_view_company_other_jobs

All About You 

Position Summary: 

As a Bioinformatics Scientist in the Product Content group of the Life Science and Applied Markets Business Unit, you will play an integral role in enabling custom genomics solutions for Illumina customers. Primary responsibilities will include providing bioinformatics support to commercial teams, customers, and within the Product Content group.

Tasks and Responsibilities: 
  • Support sales and marketing teams by providing bioinformatics analysis of sequencing and array content for pre-sale activities.
  • Provide bioinformatics support to Product Content Project managers to assist with Illumina Concierge Service projects
  • Create and maintain an internal bioinformatics tools repository with documentation
  • Generate summary statistics for new custom panels for use by sales and marketing teams
  • Create workflows to perform routine analyses
Requirements: 

We seek demonstrated accomplishment in some or all of the following skills:
  • Familiarity with linux and command line driven analysis tools
  • Ability to create workflows using bash scripting, perl, python, C++ or R
  • Experience with HPC Linux clusters and similar large systems
  • Next Gen sequencing technology, tool usage, and data analysis
  • Microarray technology, tool usage, and data analysis
  • Understanding & familiarity with public genetic databases and methods to find and extract data from the databases (NCBI, UCSC, ENSEMBL, ENCODE, 1000genomes, NHGRI)
  • Familiarity with linkage disequilibrium and imputation analyses
  • Ability to manage changing priorities and multi-task
  • Strong initiative and desire to tackle difficult problems
  • Critical problem solving and data analysis
  • Superior written and verbal communication skills
  • Ability to travel on occasion 1-3 times per year 
Education:

  • PhD (preferred) in computer science, mathematics, statistics, bioinformatics, or equivalent.
  • Genomics experience strongly preferred 

Thursday, 29 October 2015

New publication on tumour organoids using SOLiD sequencing

I am surprised to see the SOLiD machine still churning out sequence data, I had assumed that it's reached it's EOL.
but good to see that it's still serving the scientific community under the good hands of Edwin Cuppen.

http://www.pnas.org/content/112/43/13308.abstract

Preserved genetic diversity in organoids cultured from biopsies of human colorectal cancer metastases

  1. Emile E. Voesta,c,d,i,1
  1. Contributed by Hans Clevers, August 24, 2015 (sent for review April 23, 2015; reviewed by Walter F. Bodmer and Calvin Kuo)

    Significance

    Chemotherapy has been proven in clinical studies to improve overall survival significantly. Unfortunately, there is a significant degree of heterogeneity in tumor chemosensitivity, often resulting in unnecessary treatment and needless exposure to toxic side-effects. A platform is needed that can identify preemptively which patients will or will not benefit from treatment. Tumor organoids, 3D cultures of cancer cells, present such an individualized platform. In this study we demonstrate that organoid cultures can be established from metastatic biopsy specimens with a high success rate and genetically represent the metastasis they were derived from. These data support the translation of this innovative technology to the clinic as an ex vivo screening platform for tailoring treatment.

    Abstract

    Tumor organoids are 3D cultures of cancer cells. They can be derived from the tumor of each individual patient, thereby providing an attractive ex vivo assay to tailor treatment. Using patient-derived tumor organoids for this purpose requires that organoids derived from biopsies maintain the genetic diversity of the in vivo tumor. In this study tumor biopsies were obtained from 14 patients with metastatic colorectal cancer (i) to test the feasibility of organoid culture from metastatic biopsy specimens and (ii) to compare the genetic diversity of patient-derived tumor organoids and the original tumor biopsy. Genetic analysis was performed using SOLiD sequencing for 1,977 cancer-relevant genes. Copy number profiles were generated from sequencing data using CopywriteR. Here we demonstrate that organoid cultures can be established from tumor biopsies of patients with metastatic colorectal cancer with a success rate of 71%. Genetic analysis showed that organoids reflect the metastasis from which they were derived. Ninety percent of somatic mutations were shared between organoids and biopsies from the same patient, and the DNA copy number profiles of organoids and the corresponding original tumor show a correlation of 0.89. Most importantly, none of the mutations that were found exclusively in either the tumor or organoid culture are in driver genes or genes amenable for drug targeting. These findings support further exploration of patient-derived organoids as an ex vivo platform to personalize anticancer treatment.

    Datanami, Woe be me